This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
2010 | 2009 | 2008 | 2007 | 2006 |
- August 04, 2010
Targacept Reports Second Quarter 2010 Financial Results - August 03, 2010
Targacept Makes Strategic Additions to Inflammatory Disorders Program - July 28, 2010
Targacept to Report Second Quarter 2010 Financial Results on August 4, 2010 - June 23, 2010
AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214 as an Adjunct Treatment for Major Depressive Disorder - May 19, 2010
Targacept Initiates Phase 2 Study of TC-5619 in Attention Deficit/Hyperactivity Disorder in Adults - May 18, 2010
Targacept Announces Participation in Upcoming Conferences - May 05, 2010
Targacept Reports First Quarter 2010 Financial Results - May 03, 2010
Targacept and AstraZeneca Agree to Expanded TC-5619 Development Program - April 28, 2010
Targacept to Report First Quarter 2010 Financial Results on May 5, 2010 - April 26, 2010
Targacept to Present at Deutsche Bank Securities 35th Annual Health Care Conference - March 17, 2010
Targacept to Present at Barclays Capital 2010 Global Healthcare Conference - February 11, 2010
Targacept Reports Fourth Quarter and 2009 Financial Results - February 08, 2010
Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease - February 04, 2010
Targacept to Report Fourth Quarter and 2009 Financial Results on February 11, 2010 - February 02, 2010
Targacept to Present at BIO CEO & Investor Conference - January 11, 2010
Targacept Receives $200 Million Upfront Payment from AstraZeneca